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Drug Loaded Gingival Mesenchymal 
Stromal Cells (GinPa-MSCs) 
Inhibit In Vitro Proliferation of Oral 
Squamous Cell Carcinoma
Valentina Coccè1, Davide Farronato2, Anna Teresa Brini1,3, Carla Masia1, Aldo Bruno Giannì1,4, 
Giovanna Piovani5, Francesca Sisto1, Giulio Alessandri6, Francesca Angiero7 & Augusto 
Pessina1
Human mesenchymal stromal cells (MSCs) have been widely investigated both for regenerative 
medicine and their antinflammatory/immunomodulatory capacity. However, their ability to home 
pathological tissues suggested the development of strategies for using MSCs as carrier to deliver 
drug into tumor microenvironment. MSCs obtained from different tissues can be loaded in vitro with 
anti-cancer drugs by a simple procedures. In this report, we studied MSCs isolated and expanded 
from gingival papilla (GinPa-MSCs), by testing their ability to uptake and release three important anti-
neoplastic drugs: Paclitaxel (PTX), Doxorubicin (DXR) and Gemcitabine (GCB). The efficacy of drugs 
releasing GinPa-MSCs was studied on a pancreatic cancer cell line and confirmed in vitro against a line 
of tongue squamous cell carcinoma (SCC154). Our results demonstrated that GinPa-MSCs efficiently 
incorporate the drugs and then released them in active form and in sufficient amount to produce a 
dramatic inhibition of squamous cell carcinoma growth in vitro. If compared with other MSCs sources, 
the collection of GinPa-MSCs is poorly invasive and cells can be easily expanded and efficiently loaded 
with anti cancer drugs. In particular, gemcitabine loaded GinPa-MSCs provide a good “cell-mediated 
drug delivery system” for a future potential application in the context of the oral oncology.
Head and neck carcinoma are primarily originated from lip-oral cavity, pharynx and larynx and 95% of them 
are classified as squamous cell carcinoma (SCC) These type of cancers are still a significant cause of death in the 
world1, although progress have been obtained both by surgical and chemo-radiation treatment. In fact, these 
treatments of SCC reduce important side effects, but unfortunately, they are not balanced by significant increase 
in the survival rate. Treatment failure often results in a tumour recurrence and also metastasis2 that must be 
treated with chemotherapy3, 4. In this context, it could be an important goal to develop new approaches both for 
the first line treatment and in the long run for the second line one. Methotrexate remains a standard for treating 
patients with advanced, recurrent or metastatic SCC, but also cisplatin/fluorouracil or cisplatin/taxane as well 
as single-agent taxane are considered alternatives5. In a recent Phase II clinical trial, the gemcitabine-paclitaxel 
treatment has been also considered as second line treatment applied to patients who did not respond to cisplatin 
in association with radiotherapy6.
To develop more specific and less toxic treatments of cancer, the use of cells, mesenchymal stromal cells 
(MSCs) in particular, has been proposed for the drug delivery. In fact, MSCs seem to have the capacity to migrate 
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towards inflammatory microenvironments and to reach tumour sites after their systemic administration. To 
develop new therapeutic approaches based on anti-cancer molecules MSC-mediated delivery, engineered MSCs7, 8  
were used; in addition, the ability of MSCs to uptake and release drugs without any genetic manipulation9–11 was 
also exploited. Among the different sources of MSCs, studies have been conducted using bone marrow MSCs that 
have some limitations particularly concerning the discomfort caused in the donors. For this purpose, the ability 
of different sources of MSCs to uptake/release drugs9–13 has been evaluated. Among the different MSC sources, 
those from gingival could be an interesting model as they are easy to obtain with minimal invasive procedure 
and easy to expand with a few passages. In this work, we studied their ability to uptake the anti-neoplastic drugs 
Doxorubicin (DXR) and Gemcitabine (GCB) in comparison with Paclitaxel (PTX). We put particular attention 
in verifying the in vitro anticancer activity of the drug-releasing GinPa-MSCs against a tongue squamous cell 
carcinoma cell line (SCC154).
Methods
Ethics statements. Samples from adult donors were collected after written informed consent in accord-
ance with the Declaration of Helsinki; the approval for sample use was obtained from the Institutional Ethical 
Committee of IRCCS Cà Granda Ospedale Maggiore Policlinico of Milan (#978).
Mesenchymal stromal cells. Human gingival MSCs were isolated, expanded and characterized as pre-
viously described13. Briefly, the discarded gingival tissue from reductive gingivoplasty were collected in sterile 
conditions and transferred to the Cell Culture Laboratory to be processed. The samples were minced with surgical 
scissors, digested by type I Collagenase (50 U/ml, Life technologies, UK) at 37 °C under stirring condition for 
3 hours, and centrifuged (300 × g for 10 minutes). Cellular pellets were plated in 25 cm2 flask in Dulbecco’s mod-
ified Eagle’s medium with high glucose (DMEM HG) supplemented with 10% Foetal bovine serum (FBS) and 
1% L-glutamine (all reagents Euroclone, UK), maintained at 37 °C, 5% CO2, and selected by plastic adherences. 
Primary cultures were analysed for their proliferation rate (Population doubling time), clonogenicity (CFU-F 
assay), expression of the typical mesenchymal stem cell markers (high expression of CD73, CD90 and CD105; a 
mild expression of CD14 and negative for CD45) and multi-differentiative ability towards mesodermal lineages 
(osteogenic, adipogenic and chondrogenic differentiation).
Tumor cell line. The human squamous cell carcinoma line (SCC154)14 and the human pancreatic adenocar-
cinoma cell line CFPAC-115, 16 were provided by Centro Substrati Cellulari, ISZLER (Brescia, Italy). Cells were 
maintained in DMEM HG +10% FBS +1% Non essential aminoacid (SCC154) and Iscove modified Dulbecco’s 
medium (IMDM) +10% FBS (CFPAC-1), by 1:5 weekly dilution. All reagents were provided by Euroclone, UK.
Drug sensitivity of GinPa-MSCs, SCC154 and CFPAC-1 to PTX, DXR and GCB. The sensitivity of 
GinPa-MSCs to chemotherapeutic drugs Paclitaxel (PTX, kindly provided by Freseneius-Kabi. Italy; stock solu-
tion 6 mg/ml), Doxorubicin hydrochloride (DXR, Alexis biochemicals, Switzerland, stock solution 5 mg/ml) and 
Gemcitabine hydrochloride (GCB, Accord Healthcare Limited, UK, stock solution 38 mg/ml), was determined by 
adding the drugs at increasing concentrations from 0.01 to 10 μg/ml (cytotoxicity assay) or from 0.39 to 100 ng/ml 
(anti-proliferative assay). The MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-Htetrazoliumbromide) assay 
was performed after 24 hours (cytotoxicity) or after 7 days (anti-proliferation)17. The inhibitory concentrations 
(IC50 and IC90) were determined according to the Reed and Muench formula18.
Drug loading of GinPa-MSCs with PTX, DXR and GCB. The drug loading of GinPa-MSCs was per-
formed by priming the cells according to a standardized procedure that use high drug dosage as previously 
described9, 13. Briefly, subconfluent cultures (2 × 104 cells/cm2) were exposed to 2 µg/ml PTX, or DXR, or GCB 
for 24 hours. Then, the cells were washed twice with PBS, trypsinized and washed twice in Hank’s solution 
(HBSS, Euroclone UK). Drug-primed cells (GinPa-MSCs/PTX, GinPa-MSCs/DXR, GinPa-MSCs/GCB) were 
then seeded in a 25 cm2 flask in DMEM high glucose with 10% FBS and 2 mM L-glutamine (Euroclone, UK) 
to release the drug. After 48 hours, conditioned media (CM), (GinPa-MSCs/PTX CM, GinPa-MSCs/DXR CM 
GinPa-MSCs/GCB CM) were collected and tested in vitro for their anti-proliferative activity on SCC154 cells 
and CFPAC-1 cells (used as standard assay). Conditioned Media from unprimed MSCs were used as control. To 
determine the amount of drug internalized and not released, cells collected after the releasing phase were lysed 
by three sonication cycles of 0.4 second pulse cycle and 30% amplitude each (Labsonic U Braun). Lysates from 
PTX, DXR and GCB primed cells (GinPa-MSCs/PTX LYS, GinPa-MSCs/DXR LYS, GinPa-MSCs/GCB LYS) and 
unprimed GinPa-MSCs were tested for their anti-proliferative activity.
In vitro anti cancer assay on SCC154. The inhibitory effect of CM from drug loaded GinPa-MSCs and 
cell lysates were evaluated on SCC154 proliferation by the MTT assay17 and the inhibitory concentration IC50 
was determined according to the Reed and Muench formula18. The anti-tumoral activity of GinPa-MSCs/PTX 
CM, DXR CM and GCB CM were compared to that of the pure drugs (PTX, DXR and GCB) alone and expressed 
as drug equivalent concentration (DEC), according to the following algorithm: DEC (ng/ml) = IC50 Drug(ng/
ml) × 100/ IC50 CM (µl/well). The IC50 Drug is the concentration (ng/ml) of pure drug able to inhibit SCC154 
proliferation by 50%; IC50CM is the volume (µl/well) of CM inhibiting SCC154 proliferation by 50%. To evaluate 
the drug released by a single primed cell (CDR = cell drug release), an arbitrary internal parameter based on the 
ratio between the DEC and the number of seeded cells [CDR (pg/cell) = DEC (ng/ml) × 103 × CM volume (ml)/
number of seeded cells] was used.
The effect of drug released by GinPa-MSCs to SCC154 was also observed as damage exerted on tumor 
cells plated in 96 well plates (20000 cells/well). After 24 hour incubation at 37 °C and 5% CO2 to allow cellu-
lar adhesion, the culture medium was replaced by GinPa-MSCs lysate from both unprimed and PTX, DXR or 
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GCB-primed cells. After 48 hour incubation, cells were visualized with optical microscope to evaluate the apop-
totic and necrotic effects.
Secretome analysis. The CM from GinPa-MSCs were analysed for their cytokines/chemokines content 
by using multiplex bead-based assays on xMAP technology (Bio-Plex Human Cytokine 27-Plex Panel; Bio-Plex 
Human Group II Cytokine 21-Plex Panel; Biorad Laboratories). As the assay is forecasted to analyse 48 different 
cytokines, in our study we considered only the cytokines that were found in the conditioned media at levels >of 
1,500 pg/ml.
Expression of Concentrative Nucleoside Transporter-1 (hCNT-1) and equilibrative nucleoside 
transporter 1 (hENT-1) by GinPa-MSCs. The expression of hCNT-1and hENT-1 gene was evaluated by 
qRT-PCR technique as previously described19, 20. Briefly, RNA was isolated from cultured cells by Trizol (Life 
technologies, USA) and transcribed into cDNA using random primers, ribonuclease inhibitor and M-MLV 
reverse transcriptase (Life technologies, USA). The qRT-PCR analysis was performed using SYBR Green on a 
real-time PCR system 7500 and 7500 System SDS Software (Applied Biosystems, USA).
Statistical analysis. Data are expressed as average ± standard deviation (SD). Differences between mean 
values were evaluated according to Student’s t-test performed by GRAPHPADINSTAT program (GraphPad 
Software Inc., San Diego, CA, USA). p values ≤ 0.05 were considered statistically significant.
The linearity of response and the correlation were studied using regression analysis, by Excel 2013 software 
(Microsoft, Inc.).
Data availability. All data generated or analysed during this study are included in this published article.
Results
Sensitivity of CFPAC-1 and SCC154 to the anti-proliferative activity of PTX, GCB and DXR. The 
in vitro activity of PTX, GCB and DXR evaluated on the two human carcinoma cell lines CFPAC-1 and SCC154 
showed a similar dose-response kinetics (Fig. 1). The CFPAC-1 and SCC154 resulted about 3–4 time more sen-
sitive to GCB (IC50 value: 0.66 ± 0.23 ng/ml for CFPAC-1 and 0.95 ± 0.40 ng/ml for SCC154) than to PTX (IC50 
value: 2.21 ± 1.87 ng/ml for CFPAC-1 and 2.11 ± 1.10 ng/ml for SCC154) and almost 10 times more sensitive if 
compared to DXR (IC50 value: 10.62 ± 2.09 ng/ml for CFPAC-1 and 7.39 ± 2.17 ng/ml for SCC154).
Sensitivity of GinPa-MSCs to PTX, GCB and DXR. The three drugs tested for their antiproliferative 
activity on GinPa-MSCs confirmed that GinPa-MSCs were less sensitive to these anticancer molecules than can-
cer cells with a range from 2 times for GCB to 51 times for DXR. By comparing the IC50 values, GCB resulted 
the most active molecule (IC50 = 1.46 ± 0.24 ng/ml), followed by PTX (IC50 = 18.57 ± 8.26 ng/ml) and by DXR 
(IC50 = 74.78 ± 60.73 ng/ml) (Fig. 2A,B,C).
Figure 1. Sensitivity of CFPAC-1 (pancreatic adenocarcinoma line) and SCC154 (squamous cell carcinoma 
line) to the anti-proliferative activity of PTX, GCB and DXR. The effect of increasing concentrations (from 
0.195 ng/ml to 100 ng/ml) of PTX (A), GCB (B) and DXR (C), was evaluated by a 7-day anti-proliferation assay. 
The effect is expressed as percentage of the Optical Density measured in cultures that did not receive drugs 
(100% proliferation). PTX = Paclitaxel; GCB = Gemcitabine; DXR = Doxorubicine.
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The expression of the two main GCB transporters (hCNT-1 and hENT-1) by GinPa-MSCs was evaluated by 
RT-PCR compared with that of pancreatic cancer CFPAC-1 cell line (Fig. 2D). The high sensitivity to GCB well 
correlates with the expression of the main GCB transporter hENT1 that is considered the main carrier involved 
in gemcitabine transport21.
The drug sensitivity of GinPa-MSCs, measured as cytocidal effect after 24 hours of treatment confirmed some 
degree of resistance. At concentrations up to 10,000 ng/ml GinPa-MSCs, cell mortality of the treated cells was 
close to 20%. (Fig. 2E). This allowed to apply the standard procedure for drug loading based on high drug dosage 
treatment (2,000 ng/ml).
PTX, GCB and DXR uptake-release by GinPa-MSCs assessment on CFPAC-1 cells. The condi-
tioned media (GinPa-MSCs/PTX CM, GinPa-MSCs/GCB CM and GinPa-MSCs/DXR CM) and the correspond-
ing cell lysate (GinPa-MSCs/PTX LYS, GinPa-MSCs/GCB LYS and GinPa-MSCs/DXR LYS) from drug-primed 
cells were tested on the standard laboratory cell line CFPAC-1 (Fig. 3). All the CMs affected CFPAC-1 cell growth 
according to a dose-dependent, anti-proliferative effect equivalent to the one produced by free PTX (from 0.78 
to 100 ng/ml). The cell lysates of PTX and GCB-loaded cells (GinPa-MSCs/PTX LYS, GinPa-MSCs/GCB LYS) 
exerted a significant inhibition of cell proliferation, while no inhibition was exerted by GinPa-MSCs/DXR LYS 
that only produced a small, not significant effect at the highest concentration. The above described inhibitory 
kinetics analyzed by linear regression showed high coefficients of determination (R2) ranging from 0.74 to 0.84. 
The biological dosage of the CM and LYS, based on the standard dose-response regression of the pure drugs ena-
bled the estimation of an equivalent drug concentration (DEC) of incorporated (LYS) and released (CM) drug 
by a single cell (CDR) ranging from 0.075 pg/cell for GCB to 0.69 pg/cell for DXR (Fig. 4B). The percentage of 
drug released by cells in the CM referred to the total amount incorporated confirmed that at 24 hour culture, the 
cells released 62.6% of PTX, 91.8% of GCB and 100% of DXR (Fig. 4A). The drug concentrations released by 106 
GinPa-MSCs were 75 ng for GCB, 150 ng for PTX and 669 ng for DXR, respectively, that correspond to values of 
67.87, 113.63 and 64.97 times the IC50 values, respectively.
Anticancer activity against squamous carcinoma SCC154. The conditioned medium obtained 
from untreated GinPa-MSCs did not cause any modulation of the SCC154 proliferation (R2 = 0.004, p = 0.48) 
(Fig. 5A). The same conditioned medium was analysed in a microarray assay for 48 cytokines/growth factors 
and molecules detected at concentrations above 2 ng/ml are summarized in Fig. 5B. The GinPa-MSCs produced 
Figure 2. Sensitivity of GinPa-MSCs to PTX, GBC and DXR and hCNT1, hENT1 expression. The effect of 
increasing concentrations (from 0.78 ng/ml to 1000 ng/ml) of PTX (A), GCB (B) and DXR (C), was evaluated by 
a 7-day anti-proliferation assay. The effect is expressed as percentage of the Optical Density measured in cultures 
that did not receive drugs (100% proliferation) and the IC50 values by Reed and Muench formula are reported 
in the graphs. The histogram (D) reports the expression of hCNT1 and hENT1 in GinPa-MSCs compared 
with CFPAC-1 (positive control) evaluated by qRT-PCR analysis as described in Materials and Methods. 
The histograms reports the mean value of relative quantification (RQ) versus housekeeping gene (GAPDH) 
performed in duplicate. The cytotoxic activity of PTX, GCB and DXR (E) was evaluated at 24 hours of treatment 
with increasing concentrations of drugs (from 0.1 to 10 μg/ml). The data are expressed as mean ± standard 
deviation (SD) of cell viability (% of control cells) of three independents experiments.
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significant concentrations of some cytokines (Hu IL-6, Hu IL-8, Hu VEGF, Hu GROa, Hu SCGF-b; ranging from 
13 to 24 ng/ml) but their presence in the secretoma do not seem to have some inhibiting or enhancing effect on 
SCC154 proliferation. On the contrary, the anti-tumor activity of the CM from GinPa-MSCs/PTX, GinPa-MSCs/
GCB and GinPa-MSCs/DXR evaluated on SCC154 showed a dramatic inhibition of cancer cell growth. The study 
by linear regression of the dose response kinetics evidenced a significant coefficient of correlation (R2) ranging 
from 0.77 to 0.88 (Fig. 6).
Figure 3. PTX, GCB and DXR uptake and release by GinPa-MSCs tested on CFPAC-1 cells. The effect of 
conditioned media (CM) and lysate (LYS) from GinPa-MSCs/PTX (A), GinPa-MSCs/GCB (B) and GinPa-
MSCs/DXR (C), are expressed as percentage of CFPAC-1 proliferation referred to that of untreated cells (100% 
proliferation). Values are expressed as mean ± standard deviation (SD) of three independent experiments. The 
regression and the correlation coefficient (R2) of the dose response kinetics are reported in figure (D).
Figure 4. Percentage of drug incorporated and released. The histogram (A) reports the percentage of drugs 
estimated by biological dosage in the conditioned medium (CM) and cell lysate (LYS). The box (B) reports the 
IC50 value of the drugs (ng/ml) of the conditioned medium and lysate (µl/well) used to estimate the amount 
of drugs incorporated (LYS, ng total) or released (CM, ng total) by GinPa-MSCs. Values are expressed as 
mean ± standard deviation (SD) of three independent experiments. The box (C) reports the amount of drugs 
potentially delivered by 106 GinPa-MSCs and their ratio to the IC50 values of each drug. CDR = Single cell drug 
release.
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Discussion
The success of cancer chemotherapy consists of kill as many cancer cells as possible and producing the fewer pos-
sible toxic effects. With this intent, many strategies have been developed, including those based on new formula-
tions of old anticancer compounds combined with new constructs as carriers such as nanoparticles, liposomes, 
proteins, etc. This strategy is based on the protection of the drug from degradation, the promotion of drug uptake 
by tumour mass as well as lower toxicity in healthy cells22. To improve the above strategies we evaluated the use 
of MSCs for the drug delivery9, 13 and we optimized the use of gingiva- derived MSCs (GinPa-MSCs) to uptake 
and release important and widely used anticancer agents DXR, GCB and PTX. For this purpose we applied to the 
SCC154 squamous carcinoma cell line the procedure we previously standardized for pancreatic carcinoma cells 
(19). In fact, although significant improvement in survival rate has been obtained in oral squamous carcinoma 
treatment, current therapies still cause severe toxicity that makes it necessary further research for more efficacious 
and safer new agents and treatments23.
In a first step, we compared the sensitivity of SCC154 to the three drugs according to a dose–response kinetics 
that evidenced the significant higher activity of GCB (Fig. 1). This result is in agreement with recent reports24, 25  
suggesting gemcitabine as alternative agent to treat advanced squamous cell carcinoma. As expected, also the 
Figure 5. Effect of GinPa-MSCs secretome on proliferation of SCC154. The effect of the physiological 
conditioned media (CM) from GinPa-MSCs were evaluated as percentage of the proliferation of squamous 
cell carcinoma (SCC154) referred to the control. The study of the regression (R2) is reported. The histogram 
(B) report the amount of the main cytokines detected in the GinPa-MSCs secretoma (only that were present at 
levels >1,500 pg/ml).
Figure 6. Anticancer activity against squamous cell carcinoma (SCC154) of conditioned medium (CM) from 
drug loaded GinPa-MSCs. The effect of conditioned media (CM) from GinPa-MSCs/PTX (A), GinPa-MSCs/
GCB (B) and GinPa-MSCs/DXR (C), are expressed as percentage of the proliferation of SCC154 referred to that 
of untreated cells (control 100% proliferation). Values are expressed as mean ± standard deviation (SD) of three 
independent experiments. The regression and the correlation coefficient (R2) of the dose response kinetics are 
reported in figure (D).
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proliferation of GinPa-MSCs was dramatically affected by the three drugs and the highest activity was expressed 
by GCB (Fig. 2). The significant higher expression of hENT1 (the main carrier involved in gemcitabine transport 
in tumor cells)21 by GinPa-MSCs could explain the high sensitivity of GinPa-MSCs to GCB. (Figure 2D). The 
resistance of GinPa-MSCs to the cytocydal effect of GCB, DXR and PTX with, over 80% of living cells (Fig. 2D) 
enabled us to apply our standardized procedure of drug priming at very high concentration (2,000 ng/ml).
GinPa-MSCs were able to uptake and then release the three drugs in their conditioned medium. The antican-
cer activity was evaluated by a biological dosage assay against the carcinoma CFPAC-1 cells in both cell lysate 
and conditioned medium (Fig. 3). After 24 hour culture, drug-loaded GinPa-MSCs released approximately 60% 
of PTX internalized and approximately 90% and 100% of GCB and DXR, respectively (Fig. 4A). This proba-
bly reflects the different hydro-lipo-solubility of the dugs (eg: PTX is the most lipophilic and released in minor 
amount). Being GCB a pro-drug, this was an important confirmation that GCB was not inactivated by cell 
metabolism. Based on the evaluation of drug equivalent concentration (Fig. 4B), we estimated that each primed 
GinPa-MSCs could release 75 to 690 ng per 106 cells (Fig. 4C). Furthermore, the CM of drug loaded Ginpa-MSCs 
exerted also a dramatic inhibition of the squamous carcinoma SCC154 proliferation.
Although the above results need to be confirmed by preclinical studies, they can be of help in predicting the 
drug concentration that could be possibly carried into the tumour environment in vivo. By applying the criteria 
adopted for cell therapy (i.e., 2 × 106 MSCs/kg), we can estimate that the homing of such amount of MSCs to 
the tumour mass (or their in situ injection) can enable a local drug concentration at levels several times the IC50 
values determined in vitro. In this context, to exclude a possible “collateral effect” resulting in a cancer stimula-
tion exerted by GinPa-MSCs secretoma, we analysed the main cytokines/growth factors produced (Fig. 5B). The 
results confirmed that, in spite of high production of some factors (Fig. 5A), the secretoma of Ginpa-MSCs does 
not affect the in vitro growth of SCC154 whereas CM from drug primed GinPa-MSCs are very efficient in block-
ing tumor cell growth (Fig. 6).
The ability of GinPa-MSCs to uptake and release DXR allow us to discuss also some aspects concerning the 
toxicity that has been described for DXR new formulations (eg. pegylated liposomal doxorubicin, PLD). In fact, 
despite the significant decrease in cardiotoxic effects26 of these new DXR formulation, severe observations have 
been reported on their capacity to induce development of SCC as secondary malignancy. A secondary cancer 
may depend on many factors (e.g., the environment, food, pollutions etc.) and some cases are described that are 
drug treatment-related(eg: bladder cancer in cyclophosphamide or leukemia in alkylating agents treatment)27. 
However, some authors reported the cases of patients with ovarian cancer who developed squamous cell carci-
nomas after long treatment with PLD28–30; according to the authors, the long exposition to DXR released by PLD 
exerts to a toxic effect more significant than that exerted by free/non liposomal DXR, probably due to the specific 
accumulation of PDL into the oral mucosa. Although our data need to be further verified, they suggest that the 
treatment in situ of the ovary carcinoma by using DXR-loaded MSCs could avoid the mechanism of oral PLD 
concentration described.
As stated by Gisbon et al.3, the clinical management of squamous cell carcinomas can have benefit by using 
different approaches. One of them could be the drug delivery by MSCs, in particular from gingiva that according 
to Tomar et al.31, can be considered a better source of MSCs than the bone marrow. In addition, the collection of 
autologous GinPa-MSCs is an easy procedure that can be performed without any discomfort for the patient and 
it can be easily expanded to obtain large number of mesenchymal stromal cells also for banking. The use gingival 
MSCs as a carrier for delivery anti-tumor molecules is of great interest also for the anatomic homology of the 
source with the type of cancer originating into the oral cavity. This means that drug loaded GinPa-MSCs with 
anticancer agents, GCB or PTX in particular, could be suitable for possible in situ advanced cell therapies (e.g., 
in pre-cancerous stage, as adjuvant therapy to reduce the toxicity related to systemic treatment, to prevent cancer 
recurrences after surgical treatment, to reduce the radiation treatment effects, etc.
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